Tenvie Therapeutics Began First Human Trial of TNV313
The company has dosed its first patient in a Phase 1 study for an NLRP3 inhibitor designed to cross the blood-brain barrier.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you believe current biotechnology clinical trial timelines are fast enough to address serious health conditions?
Tenvie Therapeutics has initiated a Phase 1 clinical trial for TNV313, its third drug candidate to reach human studies this year. The study, which began on October 13, 2026, aims to test the safety and tolerability of this CNS-penetrant small molecule.
Why it matters
Tenvie is targeting the NLRP3 inflammasome, a protein complex involved in chronic inflammation, to treat neurologic and metabolic conditions. This trial marks the company's efforts to achieve therapeutic brain exposure at low doses.
TNV313 is a small molecule inhibitor engineered for full CNS penetration. The ongoing Phase 1 study measures single and multiple ascending oral doses to assess safety and exploratory pharmacodynamic biomarkers.
The players
Tenvie Therapeutics
A Brisbane, California-based biotechnology firm focused on developing clinical-stage NLRP3 inhibitors for neurologic and cardiometabolic diseases.
The details
The trial utilizes ascending dose cohorts to determine the safety profile of the molecule. The compound is designed to inhibit NLRP3, a protein complex that acts as a sensor for cellular stress and triggers inflammatory responses. By achieving brain exposure at lower doses, the molecule aims to mitigate neuroinflammation while minimizing systemic side effects.
Timeline
October 13, 2026: The first subject was dosed in the TNV313 Phase 1 clinical trial.
First half of 2027: Preliminary study data for TNV313 is expected to be released.
First half of 2027: Tenvie plans to initiate Phase 2 studies for the TNV262 candidate.
The Tech Race
Tenvie is competing to validate the first wave of CNS-penetrant NLRP3 inhibitors in humans. The firm is currently expanding its clinical-stage pipeline as it positions itself among researchers targeting inflammation-driven diseases.
This drug remains in the earliest stages of clinical testing and is not yet available for patient use or prescription. The trial currently impacts research workflows for clinical investigators and may inform future treatment options for neurologic and cardiometabolic conditions.
The takeaway
Tenvie is moving deeper into clinical development with a molecule designed to reach the central nervous system. Observers should track the release of preliminary Phase 1 safety data in the first half of 2027 to verify if the drug meets its target pharmacokinetic profile.
What happens next
Preliminary Phase 1 data for TNV313 is expected in the first half of 2027. Additionally, Tenvie expects to launch Phase 2 proof-of-concept studies for its TNV262 candidate during the same timeframe.
Further reading
Learn more about the latest innovations in Biotech trials and drug development trends.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current biotechnology clinical trial timelines are fast enough to address serious health conditions?
